

OPTIBIOTIX HEALTH PLC
(the "Company" or "OptiBiotix")
Grant of Options

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options, in aggregate, over 300,000 shares to employees of the Company. The options were granted on 1 June 2020 at an exercise price of 57p.

The options have performance criteria attached to them which includes revenue and profitability targets. Option holders can only exercise their options and convert to shares once the performance criteria have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Stephen O'Hara, CEO of OptiBiotix, commented: *"The ability to attract and retain key staff who deliver to revenue and profitability targets and build shareholder value is important to OptiBiotix's continued success. Granting share options helps OptiBiotix compete with remuneration packages offered by larger companies and incentivises the team to focus both effort and activity on rapidly growing revenues, reaching profitability, and building shareholder value. These options are offered to key staff and do not become exercisable until they achieve significant revenue targets which, if achieved, will create substantive shareholder value".*

For further information, please contact:

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook
below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne

Tel: 020 7220 0500

(Corporate Finance)
Camille Gochez (Corporate Broking)

Walbrook PR Ltd

Anna Dunphy

Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOESSDFLEESSEEM